Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse til evaluering af effektiviteten og sikkerheden af Belantamab Mafodotin i kombination med Cyclophosphamid, Bortezomib og Dexamethason hos voksne deltagere med nydiagnosticeret amyloid lyskæde (AL) amyloidose (ALANIS)

2. november 2026 opdateret af: GlaxoSmithKline

En fase 2, åben, enarms, proof-of-concept-undersøgelse, der evaluerer effektiviteten og sikkerheden af Belantamab Mafodotin administreret i kombination med Cyclophosphamid, Bortezomib og Dexamethason hos voksne deltagere med nyopdaget amyloid light chain amyloidose (ALANIS)

The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Fase 2

Udvidet adgang

Ledig uden for det kliniske forsøg. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • New South Wales
      • Westmead, New South Wales, Australien, 2145
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Fiona Kwok
    • Queensland
      • Woolloongabba, Queensland, Australien, 4102
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Nirija Ranjit Anderson
    • South Australia
      • Adelaide, South Australia, Australien, 5000
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Angelina Yong
    • Victoria
      • Box Hill, Victoria, Australien, 3128
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Brendan Wisniowski
      • Fitzroy, Victoria, Australien, 3065
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Matthew Rees
      • Frankston, Victoria, Australien, 3199
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Patricia Walker
        • Kontakt:
        • Kontakt:
      • Liverpool, Det Forenede Kongerige, L7 8YA
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Stephen Hawkins
      • London, Det Forenede Kongerige, NW1 2BU
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ashutosh Wechalekar
    • California
      • Los Angeles, California, Forenede Stater, 90048-1804
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Robert Vescio
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Jorge Monge Urrea
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06511
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Sabrina Browning
        • Kontakt:
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02118-2307
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Andrew Staron
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Shaji Kumar
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Pooja Phull
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Phyu Naing
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Amandeep Godara

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria:

  • Participant is at least 18 years of age or the legal age of consent

  • Has histologically confirmed newly diagnosed primary AL amyloidosis according to the following criteria:

    • Presence of an amyloid-related systemic syndrome as per consensus guidelines.
    • Positive amyloid staining by Congo red stain with green birefringence on polarized light microscopy in any tissue AND at least 1 of the following tests to confirm amyloid type as AL Characteristic appearance by electron microscopy or confirmatory immunohistochemistry or AL amyloidosis typing by mass spectrometric proteomic analysis of the amyloid deposits or amyloid-typing by immunofluorescence oEvidence of a monoclonal plasma cell proliferative disorder
  • Measurable clonal disease as defined by at least 1 of the following:

    • Serum monoclonal protein >=0.5 grams per deciliter (g/dL) by protein electrophoresis (routine serum protein electrophoresis and immunofixation performed at central laboratory),
    • Involved serum FLC >=5.0 milligram per deciliter (mg/dL) with an abnormal kappa:lambda ratio or the difference between involved and uninvolved light chain, FLC concentrations (dFLC) >=5 mg/dL.
  • Not considered candidate for high-dose chemotherapy with autologous stem cell transplantation (ASCT) as part of first line of therapy

  • Is willing to use adequate contraception.

  • Is capable of giving signed informed consent

  • Has an Eastern Cooperative Oncology Group performance status of 0, 1 or 2

  • Has adequate hematologic, hepatic and renal function

Exclusion criteria:

  • Has a previous or current diagnosis of plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS) syndrome or symptomatic multiple myeloma (MM), as per International Myeloma Working Group criteria for MM including the presence of lytic bone disease , plasmacytomas, or clonal BM plasma cells >=60%.

  • Has Immunoglobulin M (IgM)-related AL amyloidosis.

  • Has any form of non-AL amyloidosis, including wild type or mutated (Transthyretin amyloidosis [ATTR]) amyloidosis.

  • Has evidence of significant cardiovascular (CV) conditions as specified below:

    • New York Heart Association (NYHA) classification IIIb or IV heart failure.
    • Heart failure that in the opinion of the investigator is caused by ischemic heart disease (e.g., prior myocardial infarction with documented history of cardiac enzyme elevation and electrocardiogram [ECG] changes) or uncorrected valvular disease and not primarily due to AL amyloidosis cardiomyopathy.
    • In-participant admission to a hospital for unstable angina or myocardial infarction within the last 3 months prior to screening or percutaneous cardiac intervention with recent stent within last 3 months prior to screening or coronary artery bypass grafting within the last 3 months prior to screening
    • Participants with current evidence of clinically significant untreated arrhythmia(s), including clinically significant ECG abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular block.
    • Participants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular nodal or sinoatrial nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillator is indicated but not placed (participants who do have a pacemaker/implantable cardioverter-defibrillator are allowed on the study).
    • Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >450 millisecond (msec) or >480 msec for participants with bundle branch block. Participants who have a pacemaker may be included regardless of calculated QTc interval.
    • Supine systolic blood pressure <90 millimeters of mercury (mmHg), or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of >20 mmHg despite medical management (e.g., midodrine, fludrocortisones) in the absence of volume depletion.
    • Uncontrolled hypertension.
  • Has Mayo stage 3B disease

  • Has a current corneal epithelial disease except for mild punctate keratopathy.

  • Has previous or concurrent malignancies other than AL amyloidosis, except for any other malignancy that has been considered medically stable for at least 2 yearsThe participant must not be receiving active therapy, other than hormonal therapy for this disease.

  • Has major surgery within 2 weeks prior to the first dose of study interventions or has not recovered fully from surgery.

  • Has any history of prior allogenic or autologous BM transplant or other solid organ transplant.

  • Has known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, cyclophosphamide, bortezomib, boron or mannitol

  • Has active infection or active bleeding.

  • Has intolerance or contraindications to antiviral prophylaxis.

  • Has known Human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:

    • Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load <400 copies/milliliter (mL) Cluster of differentiation 4 plus (CD4+) T-cell (CD4+) counts >=350 cells/microliter.
    • No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months.
  • Has prior therapy for AL amyloidosis or MM, with the exception of 160 milligram (mg) dexamethasone (or equivalent corticosteroid) maximum exposure prior to enrollment.

  • Has received any live or live-attenuated vaccine within 30 days prior to first dose of belantamab mafodotin

  • Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of interventional medical research within 28 days before enrollment.

  • Has an alanine aminotransferase (ALT) value >2.5*upper limit of normal (ULN) or >3*ULN if hepatic involvement of AL amyloidosis

  • Has a total bilirubin value >1.5*ULN

  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment Has documented presence of Hepatitis B surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention, unless HBV DNA is undetectable at screening and participant receives antiviral prophylaxis or treatment.

  • Has a positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention unless the following criteria are met:

    • RNA test negative.
    • Successful antiviral treatment (usually 8 weeks duration), followed by a negative Hepatitis C virus RNA test after a washout period of at least 4 weeks.
  • Chronic hepatitis B infection, with the presence of HBsAg and/or detectable hepatitis B virus deoxyribonucleic acid (HBV DNA), and hepatitis D co-infection, with hepatitis D antibody and/or RNA, within 3 months

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dose optimization phase: Belantamab mafodotin dose level 1 + CyBorD

Adult participants with newly diagnosed amyloid light chain (AL) amyloidosis will receive Belantamab mafodotin dose level 1 in combination with CyBorD in dose optimization phase.

Belantamab mafodotin will be administered

Cyclophosphamide will be administered

Bortezomib will be administered

Dexamethasone will be administered

Eksperimentel: Dose optimization phase: Belantamab mafodotin dose level 2+ CyBorD

Adult participants with newly diagnosed AL amyloidosis will receive Belantamab mafodotin dose level 2 in combination with CyBorD in dose optimization phase.

Belantamab mafodotin will be administered

Cyclophosphamide will be administered

Bortezomib will be administered

Dexamethasone will be administered

Eksperimentel: Dose expansion phase: Belantamab mafodotin + CyBorD

Adult participants with newly diagnosed AL amyloidosis will receive belantamab mafodotin at selected dose level from dose optimization phase in combination with CyBorD in dose expansion phase.

Belantamab mafodotin will be administered

Cyclophosphamide will be administered

Bortezomib will be administered

Dexamethasone will be administered

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall complete hematologic response (CHR) rate
Tidsramme: Up to approximately 24 months

The overall CHR rate is defined as the proportion of participants who achieve a CHR during or after study treatment initiation, as assessed by the investigator, according to the consensus guidelines for AL amyloidosis.

Up to approximately 24 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Antal deltagere med ikke-alvorlige bivirkninger og alvorlige bivirkninger
Tidsramme: Op til cirka 24 måneder
Op til cirka 24 måneder
Antal deltagere med klinisk signifikante ændringer i hæmatologi- og kemi-parametre
Tidsramme: Op til cirka 24 måneder
Op til cirka 24 måneder
Antal deltagere med okulære fund ved oftalmologisk undersøgelse
Tidsramme: Op til cirka 24 måneder
Op til cirka 24 måneder
Maksimal plasmakoncentration (Cmax) for belantamab mafodotin
Tidsramme: Op til 24 måneder
Op til 24 måneder
Området under koncentrationstidskurven (AUC) for belantamab mafodotin
Tidsramme: Op til 24 måneder
Op til 24 måneder
Cmax for Cystein maleimidocaproyl monomethyl auristatin F (cys-mcMMAF)
Tidsramme: Op til 24 måneder
Op til 24 måneder
AUC for cys-mcMMAF
Tidsramme: Op til 24 måneder
Op til 24 måneder
Antal deltagere med positive anti-lægemiddel-antistoffer (ADA'er) mod belantamab mafodotin
Tidsramme: Op til cirka 24 måneder
Op til cirka 24 måneder
Titre af ADA'er mod belantamab mafodotin
Tidsramme: I op til cirka 24 måneder
I op til cirka 24 måneder
Organ response rate (OrRR)
Tidsramme: Up to approximately 5 years

OrRR is defined as the proportions of participants who achieve confirmed organ response (cardiac, renal, or liver) in each organ as per consensus guidelines.

Up to approximately 5 years
Duration of CHR
Tidsramme: Up to approximately 5 years

Duration of CHR is defined for participants with CHR as the time from the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive disease.

Up to approximately 5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. juni 2026

Primær færdiggørelse (Anslået)

12. januar 2033

Studieafslutning (Anslået)

12. januar 2033

Datoer for studieregistrering

Først indsendt

31. oktober 2025

Først indsendt, der opfyldte QC-kriterier

31. oktober 2025

Først opslået (Faktiske)

5. november 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner